Keywords
Coronavirus infections
Embolism
Thrombosis
Anticoagulants
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To investigate the possible parallelism between SARS-CoV-2 infection and Pulmonary Thromboembolism (PE) events, as well as their pathophysiological mechanisms. Methods: This is an integrative review in Portuguese, English and Spanish, using the Google Academic, SCIELO and PubMed databases, from December 2019 to February 2021. Results: In a large study, including 1099 SARS-CoV-2 positive patients, it was shown that D-dimer concentration was above 0.5mg / l in 46.4% of patients, in which 60% developed severe manifestations. The high risk of thrombosis was increased by the rise in this marker, which was proven to be one of the most relevant changes in coagulation in these patients. A study using the SPSS statistics software showed that the prevalence of pulmonary embolism in patients with SARS-CoV-2 is higher than in those without the disease (26% vs. 16%), confirming data published in other studies and further highlighting the need to study this relationship. Final considerations: The incidence of PTE in patients affected with SARS-CoV-2 is constantly being reported in the bibliography, demonstrating the possible association. Further studies regarding this possible parallelism are increasingly defined.